A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)

Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs IGN 002 (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors ImmunGene
  • Most Recent Events

    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 08 Jan 2016 According to Valor Biotherapeutics media release,the first patient was dosed in this study in January 2016.
    • 18 Dec 2015 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top